Research led by Sichuan University in China has revealed that bedtime antihypertensive medication dosing improves nocturnal blood pressure control over morning dosing in patients with hypertension.
An international team of researchers led by Professor Morris Brown FRS at Queen Mary University of London found that Baxdrostat, a drug belonging to a new class of aldosterone synthase inhibitors, led to an average fall in ...
Jul 14, 2025
0
14
New research explains how low levels of the electrolyte sodium in the blood can disrupt the timing of the heartbeat in patients taking widely used rhythm-control medications such as flecainide, which is commonly prescribed ...
2 hours ago
0
0
Stroke is said to be the second leading cause of death worldwide after heart disease. To prevent the death of neurons in the brain, a research group led by Osaka Metropolitan University Associate Professor Hidemitsu Nakajima ...
5 hours ago
0
0
Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.
5 hours ago
0
0
Research presented today at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting included three studies that explored the differences in treatment and recovery options for patients across racial, gender ...
Jul 14, 2025
0
0
Endocrine Society experts encouraged more widespread screening for a common hormonal cause of high blood pressure known as primary aldosteronism in a new Clinical Practice Guideline.
Jul 14, 2025
0
0
Pharmacy researchers at the National University of Singapore (NUS) have demonstrated that multi-component interventions are required to improve the regular intake of cholesterol-lowering medications.
Jul 14, 2025
0
0
The public, legislators, and media often group per- and polyfluoroalkyl substances, known as PFAS or "forever chemicals," which are found globally in countless products, into a single category. While certain PFAS are harmful ...
Jul 14, 2025
0
1
